Hospital
Davis Memorial Hospital
Davis Memorial Hospital was paid $20.09M by Medicaid between Jan 2018 and Dec 2024, across 290 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoDAVIS MEMORIAL HOSPITAL
ELKINS, WV 26241
ELKINS, WV 26241
33aNPI1619964806assigned 10/03/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.09M
24GClaims665,743
24DCodes billed290
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#13 of 26
Median peer was paid$18.33M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 107,280 | $5.39M | |
| 2019 | 76,118 | $3.25M | |
| 2020 | 117,203 | $4.45M | |
| 2021 | 116,117 | $2.45M | |
| 2022 | 73,984 | $1.58M | |
| 2023 | 92,818 | $1.70M | |
| 2024incomplete | 82,223 | $1.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 39,750 | 33,454 | $3.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 26,169 | 21,206 | $3.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 2,719 | 2,306 | $622K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 49,940 | 37,238 | $573K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.2% | 4,784 | 4,221 | $443K |
| 80053 | Comprehensive metabolic panel | 2.0% | 22,193 | 18,607 | $411K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 28,387 | 20,709 | $371K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 3,555 | 2,512 | $359K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 1,799 | 1,539 | $309K |
| 87428 | 1.4% | 8,758 | 7,765 | $277K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 21,038 | 17,161 | $277K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1.3% | 5,150 | 3,810 | $267K |
278 more codes
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.3% | 9,238 | $267K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1.3% | 5,655 | $258K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 706 | $236K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 4,267 | $234K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 9,949 | $232K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 7,099 | $231K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 8,792 | $215K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 4,638 | $212K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,101 | $191K |
| 81001 | <1% | 20,571 | $184K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,457 | $182K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,584 | $179K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 719 | $168K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,921 | $167K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,255 | $164K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,270 | $158K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13,007 | $148K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,351 | $146K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,305 | $139K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,691 | $139K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,323 | $138K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,774 | $133K |
| 84484 | <1% | 11,284 | $133K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,183 | $129K |
| G0378 | Hospital observation service, per hour | <1% | 2,424 | $127K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,424 | $126K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,970 | $126K |
| 80061 | Lipid panel | <1% | 8,698 | $124K |
| 80076 | <1% | 9,956 | $120K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,382 | $117K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,495 | $116K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,393 | $112K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,550 | $109K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,132 | $104K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 697 | $102K |
| 87088 | <1% | 8,459 | $99K | |
| 93017 | <1% | 885 | $99K | |
| 71250 | <1% | 1,787 | $98K | |
| 44361 | <1% | 619 | $96K | |
| 83735 | <1% | 5,816 | $94K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 379 | $92K |
| 83615 | <1% | 2,940 | $90K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,245 | $86K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,156 | $86K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,982 | $86K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,509 | $77K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,187 | $75K |
| 43254 | <1% | 459 | $75K | |
| 45390 | <1% | 453 | $75K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,185 | $74K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,338 | $73K |
| 83690 | <1% | 7,145 | $70K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 952 | $70K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,381 | $67K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 398 | $64K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,605 | $62K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 500 | $61K |
| 83880 | <1% | 3,869 | $61K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,470 | $58K |
| 81025 | <1% | 2,786 | $58K | |
| 96376 | <1% | 2,787 | $57K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,030 | $57K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 29 | $57K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 507 | $56K |
| 87077 | <1% | 3,651 | $54K | |
| 87186 | <1% | 3,586 | $53K | |
| 93971 | <1% | 509 | $52K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,090 | $51K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 780 | $50K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,684 | $49K |
| 82948 | <1% | 2,269 | $47K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 519 | $44K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,641 | $44K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,520 | $44K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 604 | $43K |
| 85610 | <1% | 7,496 | $42K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 110 | $41K |
| 86140 | <1% | 5,170 | $39K | |
| 73630 | <1% | 1,904 | $39K | |
| 82607 | <1% | 2,834 | $39K | |
| 84439 | <1% | 2,769 | $37K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 891 | $37K |
| 85730 | <1% | 5,368 | $36K | |
| 82803 | <1% | 1,988 | $35K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 986 | $31K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,099 | $31K |
| 87040 | <1% | 2,253 | $31K | |
| 84703 | <1% | 1,629 | $31K | |
| 73610 | <1% | 1,264 | $31K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,267 | $30K |
| 96401 | <1% | 949 | $30K | |
| 73562 | <1% | 780 | $27K | |
| 73130 | <1% | 951 | $27K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,712 | $27K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 269 | $24K |
| 87807 | <1% | 1,473 | $24K | |
| 20610 | <1% | 936 | $23K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,413 | $23K |
| 82550 | <1% | 1,663 | $23K | |
| 85379 | <1% | 1,605 | $22K | |
| 74022 | <1% | 577 | $22K | |
| 73030 | <1% | 1,222 | $22K | |
| 83605 | <1% | 2,286 | $21K | |
| 87070 | <1% | 408 | $21K | |
| 88304 | <1% | 195 | $21K | |
| 73110 | <1% | 763 | $20K | |
| 85027 | <1% | 2,156 | $20K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 151 | $20K |
| 74018 | <1% | 823 | $20K | |
| 82728 | <1% | 1,499 | $20K | |
| 70486 | <1% | 222 | $20K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,603 | $19K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,092 | $19K |
| 84702 | <1% | 582 | $19K | |
| 46946 | <1% | 91 | $19K | |
| 99156 | <1% | 824 | $19K | |
| C8957 | Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump | <1% | 361 | $18K |
| 80081 | <1% | 261 | $18K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 762 | $17K |
| 73502 | <1% | 892 | $17K | |
| 80050 | General health panel | <1% | 530 | $17K |
| 82150 | <1% | 907 | $16K | |
| 72110 | <1% | 319 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,722 | $15K |
| 86803 | <1% | 590 | $15K | |
| 96367 | <1% | 661 | $15K | |
| 84481 | <1% | 466 | $14K | |
| 87205 | <1% | 369 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,572 | $13K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 310 | $13K |
| 11721 | <1% | 1,684 | $13K | |
| 82565 | <1% | 1,088 | $12K | |
| 83655 | <1% | 750 | $12K | |
| 80074 | <1% | 276 | $11K | |
| 84550 | <1% | 805 | $11K | |
| 82962 | <1% | 5,800 | $11K | |
| 83540 | <1% | 1,386 | $11K | |
| 86900 | <1% | 988 | $10K | |
| 86901 | <1% | 988 | $9K | |
| 82947 | <1% | 609 | $9K | |
| 80305 | <1% | 1,166 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 30 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 391 | $9K |
| 85652 | <1% | 1,229 | $9K | |
| 84520 | <1% | 445 | $9K | |
| 83550 | <1% | 1,107 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,467 | $9K |
| 85014 | <1% | 1,242 | $8K | |
| 85018 | <1% | 1,243 | $8K | |
| 74178 | <1% | 64 | $8K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 119 | $8K |
| 84482 | <1% | 247 | $8K | |
| 90715 | <1% | 215 | $8K | |
| 76641 | <1% | 111 | $7K | |
| 73560 | <1% | 430 | $7K | |
| 87653 | <1% | 186 | $7K | |
| 76770 | <1% | 84 | $7K | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 12 | $6K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 25 | $6K |
| 82043 | <1% | 907 | $6K | |
| 82570 | <1% | 833 | $6K | |
| 46930 | <1% | 27 | $6K | |
| 81002 | <1% | 1,059 | $6K | |
| 94060 | <1% | 129 | $5K | |
| 73070 | <1% | 169 | $5K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 593 | $5K |
| 84100 | <1% | 469 | $4K | |
| 73590 | <1% | 207 | $4K | |
| 85007 | <1% | 765 | $4K | |
| 90686 | <1% | 563 | $4K | |
| 93880 | <1% | 45 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 285 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $3K |
| 27096 | <1% | 17 | $3K | |
| 43233 | <1% | 22 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 389 | $3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 13 | $3K |
| 86376 | <1% | 122 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 161 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 105 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 15 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,398 | $3K |
| 76536 | <1% | 52 | $3K | |
| 12001 | <1% | 48 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $3K |
| 82950 | <1% | 184 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 21 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 100 | $2K |
| 86800 | <1% | 105 | $2K | |
| 93225 | <1% | 55 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 113 | $2K |
| 82140 | <1% | 61 | $2K | |
| 73090 | <1% | 49 | $2K | |
| 84460 | <1% | 232 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 27 | $2K |
| 36591 | <1% | 68 | $2K | |
| 86850 | <1% | 188 | $2K | |
| 84450 | <1% | 211 | $2K | |
| 76642 | <1% | 62 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,505 | $2K |
| 96523 | <1% | 122 | $2K | |
| 72100 | <1% | 86 | $1K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 13 | $1K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 107 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 18 | $1K |
| 87081 | <1% | 62 | $1K | |
| 70496 | <1% | 14 | $1K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 15 | $1K |
| 70498 | <1% | 12 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 137 | $1K |
| 94729 | <1% | 27 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 72 | $1K |
| 99157 | <1% | 39 | $1K | |
| 82248 | <1% | 61 | $1K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 100 | $1K |
| 86038 | <1% | 76 | $1K | |
| 90619 | <1% | 17 | $1K | |
| 30140 | <1% | 19 | $980.00 | |
| 94727 | <1% | 15 | $961.06 | |
| 83970 | <1% | 28 | $951.17 | |
| 62323 | <1% | 25 | $919.62 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 78 | $902.64 |
| 87808 | <1% | 70 | $894.40 | |
| 84156 | <1% | 86 | $806.92 | |
| 84153 | <1% | 54 | $797.56 | |
| 84480 | <1% | 59 | $794.18 | |
| 77066 | Tomosynthesis, mammo | <1% | 16 | $738.33 |
| 74160 | <1% | 13 | $654.82 | |
| 99490 | Ccm add 20min | <1% | 200 | $595.80 |
| 87209 | <1% | 41 | $562.78 | |
| 86618 | <1% | 41 | $554.05 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 451 | $517.33 |
| 87177 | <1% | 41 | $507.80 | |
| G0008 | Administration of influenza virus vaccine | <1% | 373 | $505.76 |
| 82274 | <1% | 18 | $501.72 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $448.44 |
| 87493 | <1% | 14 | $436.02 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 41 | $424.20 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $416.97 |
| 80164 | <1% | 18 | $393.26 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 199 | $387.04 |
| 82533 | <1% | 26 | $379.84 | |
| 72070 | <1% | 13 | $378.29 | |
| 87045 | <1% | 36 | $353.08 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 28 | $330.18 |
| 86431 | <1% | 13 | $244.79 | |
| Q3014 | Telehealth originating site facility fee | <1% | 45 | $234.96 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 927 | $230.69 |
| 77002 | <1% | 14 | $212.00 | |
| 86922 | <1% | 15 | $178.55 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 34 | $176.05 |
| 90474 | <1% | 29 | $175.34 | |
| 84145 | <1% | 30 | $170.58 | |
| A9270 | Non-covered item or service | <1% | 517 | $167.96 |
| 73564 | <1% | 36 | $167.91 | |
| 73552 | <1% | 12 | $150.26 | |
| 99201 | <1% | 17 | $146.07 | |
| 84436 | <1% | 13 | $131.22 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17 | $118.22 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14 | $101.75 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 19 | $77.54 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 49 | $73.26 |
| 76376 | <1% | 280 | $47.10 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 68 | $42.62 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 198 | $34.65 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 61 | $33.83 |
| 90744 | <1% | 14 | $29.89 | |
| 86885 | <1% | 15 | $21.44 | |
| 93356 | <1% | 239 | $19.48 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 32 | $18.01 |
| G0009 | Administration of pneumococcal vaccine | <1% | 13 | $6.46 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 60 | $0.75 |
| 90698 | 0% | 64 | $0.00 | |
| 90651 | 0% | 17 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 28 | $0.00 |
| 90680 | 0% | 17 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEMPSEY, MELANIE (INTERIM CFO)